11C ME@HAPTHI: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 1: | Line 1: | ||
{{ | {{DISPLAYTITLE:11C-Methionine PET Imaging}} | ||
== 11C-Methionine PET Imaging == | |||
[[File:11C_ME@HAPTHI.svg|thumb|right|Diagram of 11C-Methionine molecule]] | |||
11C-Methionine PET imaging is a specialized form of [[positron emission tomography]] (PET) that utilizes the radiolabeled amino acid [[11C-Methionine]] to assess metabolic activity in tissues, particularly in the context of [[oncology]]. This imaging technique is valuable for detecting and evaluating [[brain tumors]], as well as other types of [[cancer]]. | |||
== | == Mechanism of Action == | ||
11C_ME@HAPTHI is a | [[File:11C_ME@HAPTHI.svg|thumb|left|Chemical structure of 11C-Methionine]] | ||
11C-Methionine is a radiolabeled form of the essential amino acid [[methionine]], where the carbon atom is replaced with the radioactive isotope [[carbon-11]]. When administered to a patient, 11C-Methionine is taken up by cells through the same transport mechanisms as natural methionine. Tumor cells, which often have increased protein synthesis and metabolic activity, will uptake more 11C-Methionine compared to normal cells. The radioactive decay of carbon-11 emits positrons, which are detected by the PET scanner to create detailed images of metabolic activity. | |||
== | == Clinical Applications == | ||
11C-Methionine PET imaging is primarily used in the evaluation of [[brain tumors]], such as [[gliomas]]. It helps in distinguishing tumor tissue from [[necrosis]] or [[edema]], assessing tumor grade, and planning [[radiotherapy]]. Additionally, it can be used to monitor treatment response and detect [[tumor recurrence]]. | |||
== | === Brain Tumors === | ||
In the context of brain tumors, 11C-Methionine PET provides superior contrast compared to other imaging modalities like [[MRI]] or [[CT scan]], especially in low-grade gliomas. It is particularly useful in cases where [[MRI]] results are inconclusive. | |||
=== | === Other Cancers === | ||
While its primary use is in brain tumors, 11C-Methionine PET can also be applied to other cancers, such as [[head and neck cancer]], [[prostate cancer]], and [[breast cancer]], to evaluate metabolic activity and guide biopsy. | |||
== | == Advantages and Limitations == | ||
11C-Methionine PET imaging offers several advantages, including high sensitivity and specificity for detecting active tumor tissue. However, it has limitations such as the short half-life of carbon-11 (approximately 20 minutes), which requires an on-site [[cyclotron]] for production. This limits its availability to specialized centers. | |||
== Related pages == | |||
==Related pages== | |||
* [[Positron emission tomography]] | * [[Positron emission tomography]] | ||
* [[Radiopharmaceutical]] | |||
* [[Brain tumor]] | |||
* [[Carbon-11]] | * [[Carbon-11]] | ||
[[Category:Medical imaging]] | [[Category:Medical imaging]] | ||
[[Category:Nuclear medicine]] | [[Category:Nuclear medicine]] | ||
[[Category:Oncology]] | |||
Latest revision as of 10:49, 15 February 2025
11C-Methionine PET Imaging[edit]
11C-Methionine PET imaging is a specialized form of positron emission tomography (PET) that utilizes the radiolabeled amino acid 11C-Methionine to assess metabolic activity in tissues, particularly in the context of oncology. This imaging technique is valuable for detecting and evaluating brain tumors, as well as other types of cancer.
Mechanism of Action[edit]
11C-Methionine is a radiolabeled form of the essential amino acid methionine, where the carbon atom is replaced with the radioactive isotope carbon-11. When administered to a patient, 11C-Methionine is taken up by cells through the same transport mechanisms as natural methionine. Tumor cells, which often have increased protein synthesis and metabolic activity, will uptake more 11C-Methionine compared to normal cells. The radioactive decay of carbon-11 emits positrons, which are detected by the PET scanner to create detailed images of metabolic activity.
Clinical Applications[edit]
11C-Methionine PET imaging is primarily used in the evaluation of brain tumors, such as gliomas. It helps in distinguishing tumor tissue from necrosis or edema, assessing tumor grade, and planning radiotherapy. Additionally, it can be used to monitor treatment response and detect tumor recurrence.
Brain Tumors[edit]
In the context of brain tumors, 11C-Methionine PET provides superior contrast compared to other imaging modalities like MRI or CT scan, especially in low-grade gliomas. It is particularly useful in cases where MRI results are inconclusive.
Other Cancers[edit]
While its primary use is in brain tumors, 11C-Methionine PET can also be applied to other cancers, such as head and neck cancer, prostate cancer, and breast cancer, to evaluate metabolic activity and guide biopsy.
Advantages and Limitations[edit]
11C-Methionine PET imaging offers several advantages, including high sensitivity and specificity for detecting active tumor tissue. However, it has limitations such as the short half-life of carbon-11 (approximately 20 minutes), which requires an on-site cyclotron for production. This limits its availability to specialized centers.
